Previous 10 | Next 10 |
WATERTOWN, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that a late-breaking abstract featuring ...
Data provide further evidence for the central role of IRAK4 in inflammation in hidradenitis suppurativa and support both the degrader rationale for targeting IRAK4 and KT-474 development KT-474 is in Phase 1 clinical development as a first-in-class oral IRAK4 degrader for th...
WATERTOWN, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Boston Business Journal (BBJ)...
Gainers: Cinedigm (CIDM) +20%.Grupo Televisa (TV) +20%.GameStop (GME) +18%.Nurix Therapeutics (NRIX) +18%.Centennial Resource Development (CDEV) +17%.Regulus Therapeutics (RGLS) +16%.NexImmune (NEXI) +16%.UP Fintech (TIGR) +16%.Kymera Therapeutics (KYMR) +15%.Transocean (RIG) +...
Gainers: Galectin Therapeutics (GALT) +17%, NexImmune (NEXI) +16%, Kymera Therapeutics (KYMR) +15%, Nurix Therapeutics (NRIX) +15%, DBV Technologies (DBVT) +13%.Losers: LifeMD (LFMD) -24%, CorMedix (CRMD) -11%, Cleveland BioLabs (CBLI) -9...
The following slide deck was published by Kymera Therapeutics, Inc. in conjunction with this event. For further details see: Kymera Therapeutics (KYMR) Presents At AACR Virtual Meeting 2021 - Slideshow
KT-413-mediated degradation of IRAK4 and IMiD substrates has synergistic effect on MYD88-NFkB and IRF4-Type 1 Interferon pathways resulting in superior antitumor activity in MYD88-mutant DLBCL models compared to IMiDs or selective IRAK4 targeting alone Company anticipates IND su...
WATERTOWN, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that a late-breaking abstract featurin...
An update on the 20 life sciences companies Numenor Capital has profiled so far range from cell therapy companies like SQZ Biotech and Orchard Therapeutics to biologics platforms like Pandion. The best performing investment, over 170% return, so far has been Pandion Therapeutics that ...
The fund just received a huge distribution boost, making it more appealing to income-oriented investors. The latest declines in BMEZ also coincide with an attractive discount on the fund. BMEZ is an attractive long-term option in the healthcare space that focuses on new tech - tho...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...